RenovoRx (RNXT) Q1 2025 earnings summary

Executive summary

• Achieved first full quarter of commercial revenue for RenovoCath, totaling approximately $200,000 in Q1 2025, following initial launch in late 2024 and surpassing internal expectations.

• Ongoing pivotal Phase III TIGER-PaC trial for TAMP therapy in pancreatic cancer continues, with 91 of 114 patients randomized and second interim analysis underway, showing promising interim results.

• Strong physician and clinical investigator support for TAMP and RenovoCath, with positive feedback on clinical benefit and tolerability.

• Commercialization is in early stages, with sequential revenue growth expected throughout 2025.

• Management and Board purchased approximately 143,000 shares in open market, signaling confidence.

Financial highlights

• Q1 2025 revenue reached approximately $200,000, marking the first full quarter of product sales.

• Research and development expenses were $1.7 million, up from $1.3 million year-over-year, mainly due to increased compensation, manufacturing, and scale-up costs.

• Selling, general, and administrative expenses rose to $1.6 million from $1.2 million year-over-year, reflecting higher personnel and commercialization costs.

• Net loss widened to $2.4 million for Q1 2025, compared to $1.1 million in Q1 2024, reflecting higher operating expenses and a decrease in warrant liability value.

• Cash and cash equivalents totaled $14.6 million as of March 31, 2025, bolstered by a $10.8 million net equity raise in February 2025.

Outlook and guidance

• Expects sequential quarter-over-quarter revenue growth for RenovoCath for the remainder of 2025.

• Cash position anticipated to fully fund commercialization and completion of the TIGER-PaC trial, with additional capital likely needed for long-term growth and regulatory milestones.

• Full enrollment for the TIGER-PaC trial anticipated in 2025, with second interim analysis review expected in Q3.

• Exploring U.S. market expansion first, with international market entry considered for late 2025 or beyond.

• Anticipates increased expenses as commercialization and clinical activities expand.